Information for "Continuing development of your PARP inhibitor talazoparib for the treatment of advanced BRCA1 along with BRCA2 mutated breast cancer"

From EECH Central
Jump to: navigation, search

Basic information

Display titleContinuing development of your PARP inhibitor talazoparib for the treatment of advanced BRCA1 along with BRCA2 mutated breast cancer
Default sort keyContinuing development of your PARP inhibitor talazoparib for the treatment of advanced BRCA1 along with BRCA2 mutated breast cancer
Page length (in bytes)3,467
Page ID1381081
Page content languageEnglish (en)
Page content modelwikitext
Indexing by robotsAllowed
Number of redirects to this page0

Page protection

EditAllow all users (infinite)
MoveAllow all users (infinite)

Edit history

Page creatorSofaraven46 (Talk | contribs)
Date of page creation08:25, 19 April 2024
Latest editorSofaraven46 (Talk | contribs)
Date of latest edit08:25, 19 April 2024
Total number of edits1
Total number of distinct authors1
Recent number of edits (within past 90 days)1
Recent number of distinct authors1